MZ1 co-operates with trastuzumab in HER2 positive breast cancer

BACKGROUND: Although the anti-HER2 antibody trastuzumab augments patient survival in HER2+ breast cancer, a relevant number of patients progress to this treatment. In this context, novel drug combinations are needed to increase its antitumor activity. In this work, we have evaluated the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Noblejas-López, María del Mar, Nieto-Jiménez, Cristina, Galán-Moya, Eva M., Tebar-García, David, Montero, Juan Carlos, Pandiella, Atanasio, Burgos, Miguel, Ocaña, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980639/
https://www.ncbi.nlm.nih.gov/pubmed/33741018
http://dx.doi.org/10.1186/s13046-021-01907-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980639/
https://www.ncbi.nlm.nih.gov/pubmed/33741018
http://dx.doi.org/10.1186/s13046-021-01907-9

Ejemplares similares